Related Experiment Video
Updated: Jul 23, 2025
05:20
Zebrafish Model of Neuroblastoma Metastasis
Published on: March 14, 2021
2.8K
Review: Targeting EZH2 in neuroblastoma
Jinhui Gao1, Claire Fosbrook1, Jane Gibson1
1School of Cancer Sciences, Faculty of Medicine, University of Southampton, SO16 6YD, UK.
Cancer Treatment Reviews
|July 19, 2023
Summary
Enhancer of Zeste Homolog 2 (EZH2) plays a key role in neuroblastoma development. Targeting EZH2 offers a promising therapeutic strategy for this aggressive pediatric cancer, potentially improving patient survival rates.
Area of Science:
- Pediatric Oncology
- Epigenetics
- Molecular Biology
Background:
- Neuroblastoma is a common pediatric cancer with high mortality, especially in high-risk cases.
- Current treatments for neuroblastoma are intensive but have high relapse rates and resistance.
- Enhancer of Zeste Homolog 2 (EZH2) is implicated in tumorigenesis and differentiation blockade.
Purpose of the Study:
- To review the role of EZH2 in neuroblastoma.
- To evaluate the therapeutic potential of targeting EZH2 in neuroblastoma treatment.
Main Methods:
- Literature review of studies on EZH2 in neuroblastoma.
- Analysis of EZH2's function as a histone methyltransferase and its role in epigenetic regulation.
- Evaluation of preclinical and clinical research on EZH2 inhibitors.
Main Results:
- EZH2 overexpression promotes neuroblastoma growth and inhibits differentiation.
- Targeting EZH2 has shown promise in preclinical models of neuroblastoma.
- EZH2 inhibitors are being investigated as a novel therapeutic approach.
Conclusions:
- EZH2 is a critical regulator in neuroblastoma pathogenesis.
- Targeting EZH2 represents a potential new strategy to overcome treatment resistance and improve outcomes in neuroblastoma.
